COAG earnings analysis
What we found in COAG's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Hemab remains a pre-revenue clinical-stage biotechnology company with a reported second-quarter loss of $0.80 per share and no disclosed revenue, margin or free-cash-flow metrics in the supplied filing text. Liquidity is a meaningful offset: $457.5 million of cash, cash equivalents and marketable securities is expected to fund operations into 2029 following $317.2 million of IPO net proceeds. The principal issues are unresolved material weaknesses, continued substantial losses, thrombotic events in sutacimig development and uncertainty over the design and cost of the planned Phase 3 trial.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Cash runway extends into 2029
- Cash, cash equivalents and marketable securities totaled $457.5 million as of June 30, 2026, which management expects to support operating expenses and capital expenditures into 2029.
- IPO materially strengthened liquidity
- The May 2026 IPO generated approximately $317.2 million of net proceeds from the issuance of 19,262,500 shares at $18.00 per share, providing substantial funding for clinical development.
- Pipeline advances toward pivotal testing
- Management plans to advance sutacimig into a Phase 3 Glanzmann thrombasthenia trial and continue Phase 1/2 and Phase 2 programs for sutacimig and HMB-002.
- Broadening intellectual-property portfolio
- As of August 8, 2026, Hemab owned, co-owned or exclusively licensed approximately 13 issued patents and 78 pending patent applications related to its product candidates.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weaknesses remain unresolved
- Management concluded that disclosure controls and procedures were not effective as of June 30, 2026 because of 2 material weaknesses: ineffective financial-statement close controls and ineffective information-system controls covering access, segregation of duties and change management.
- Thrombotic events threaten development
- Sutacimig development includes thrombotic safety events in a Phase 1/2 trial of 34 patients: one grade 2 proximal deep-vein thrombosis occurred at 0.9 mg/kg and one grade 2 subsegmental pulmonary embolism occurred at 0.3 mg/kg. The planned Phase 3 dose is 0.2 mg/kg, but thrombotic events may still occur at lower doses.
- Large losses and future funding needs
- The company reported net losses of $46.8 million for the six months ended June 30, 2026 and an accumulated deficit of $228.7 million as of that date. Despite the stated runway into 2029, management cautions that its assumptions may prove incorrect and that additional funding will be required for registrational trials.
- FDA trial-design uncertainty
- The FDA may require a randomized controlled Phase 3 trial rather than Hemab's planned single-arm design, potentially increasing patient requirements, enrollment time and clinical costs. The company estimates only approximately 10,000 aggregate Glanzmann thrombasthenia and Factor VII deficiency patients in its target geographies.
- Trade and China supply-chain exposure
- A new risk discussion highlights potential tariffs of 10% to 100% on certain patented pharmaceuticals, biologics and ingredients beginning September 29, 2026. The filing also states that WuXi AppTec was added to the U.S. Department of Defense Chinese Military Companies list on June 8, 2026, although a 5-year grandfather clause may protect contracts through 2031.
- Potential EU exclusivity changes
- The filing identifies uncertainty from the proposed EU Pharma Package, which would establish 8 years of data exclusivity and 1 year of market exclusivity, with possible extensions capped at 11 years total; adoption is expected by fall 2026 with changes taking effect in mid-2028.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.8
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management expects cash, cash equivalents and marketable securities of $457.5 million as of June 30, 2026 to fund operating expenses and capital expenditure requirements into 2029. The company plans to initiate a Phase 3 sutacimig trial and expects additional clinical data in late 2026 or early 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 21, 2026
- Hemab Therapeutics Holdings, Inc. reported disappointing Q1 2026 results, with revenues of $0 and a net loss of $22.7 million, resulting in an EPS of -$23.98. Key drivers included increased R&D expenditures to support…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing COAG makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever